Frailty and Vulnerability as Predictors of Chemotherapy Toxicity in Older Adults: A Longitudinal Study in Peru

Runzer-Colmenares, Fernando M.; Urrunaga-Pastor, Diego; Roca-Moscoso, Max Antonio; Noriega, J. De; Rosas-Carrasco, Óscar; Parodi, José F.

doi:10.1007/s12603-020-1404-6

Cited by 12 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, the likelihood of frailty is greater among those living with chronic cardiometabolic diseases such as diabetes ( García-Esquinas et al, 2015 ), cardiovascular diseases ( Aguayo et al, 2019 ; Marinus et al, 2020 ), atrial fibrillation ( Polidoro et al, 2013 ), heart failure ( Denfeld et al, 2017 ), stroke ( Palmer et al, 2019 ), and chronic kidney diseases ( Chowdhury et al, 2017 ). Older adults with coexisting cardiometabolic diseases and frailty are less likely to tolerate advanced medical/surgical interventions such as anesthesia ( Lin et al, 2018 ), cardioverter-defibrillator placement ( Chen et al, 2019 ), surgery ( Panayi et al, 2019 ), and chemotherapy ( Runzer-Colmenares et al, 2020 ).…”

mentioning

confidence: 99%

The Association Between Cardiometabolic Risk Factors and Frailty in Older Adults: A Systematic Review

Shakya

Bajracharya

Ledbetter

et al. 2022

Innovation in Aging

View full text Add to dashboard Cite

Background and Objectives Enhanced management and prevention of frailty depend on our understanding of the association between potentially modifiable risk factors and frailty. However, the associations between potentially modifiable cardiometabolic risk factors and frailty are not clear. The purpose of this review was to appraise and synthesize the current evidence examining the associations between the cardiometabolic risk factors and frailty. Research Design and Methods Multiple databases, including MEDLINE (via PubMed), Embase (via Elsevier), and Web of Science (via Clarivate), were searched extensively. Studies that examined cardiometabolic risk factors and frailty as main predictors and outcome of interest, respectively, among older adults (≥ 60 years) were included. The Joanna Briggs Institute (JBI) critical appraisal tools were used to evaluate the quality of studies. PRISMA (2020) guided this review, and findings were synthesized without meta-analysis. This systematic review was registered in PROSPERO (CRD42021252565). Results Twelve studies met the eligibility criteria and were included in the review. Abdominal obesity, hyperglycemia, and multiple co-occurring cardiometabolic risk factors were associated with the increased likelihood of frailty in older adults. There was inconsistency across the studies regarding the associations between dyslipidemia, elevated blood pressure, and frailty. Discussion and implications Understanding the association between cardiometabolic risk factors and frailty can have translational benefits in developing tailored interventions for the prevention and management of frailty. More studies are needed to validate predictive and clinically significant associations between single and specific combinations of co-occurring cardiometabolic risk factors and frailty.

show abstract

mentioning

confidence: 99%

The Association Between Cardiometabolic Risk Factors and Frailty in Older Adults: A Systematic Review

Shakya

Bajracharya

Ledbetter

et al. 2022

Innovation in Aging

View full text Add to dashboard Cite

show abstract

“…The participants were evaluated and enrolled from September 2012 to February 2013 and were followed until 2015, in the Geriatrics Service of the Naval Medical Center of Peru (CEMENA), located in Callao, Peru. We have developed previous articles (21)(22)(23) with the present database evaluating geriatric syndromes and their risk of adverse outcomes. The initial evaluation included 1,178 eligible older adults among which 121 were subsequently excluded due to a Mini Mental State Examination (MMSE) score less than or equal to 23, 81 for having a diagnosis of dementia, nine due to a diagnosis without curative intent, four because they discontinued their treatment, four due to incomplete medical records, six due to loss to follow-up, and 31 did not agree to participate in the study (Figure 1).…”

Section: Study Design Population and Samplementioning

confidence: 99%

SARC-F and SARC-CalF Scores as Mortality Risk Factors in Older Men with Cancer: A Longitudinal Study from Peru

Ururi-Cupi

Oliva-Zapata

Salazar-Talla

et al. 2022

The Journal of nutrition, health and aging

Self Cite

View full text Add to dashboard Cite

Objectives We aimed to evaluate the role of SARC-F and SARC-CalF scores as risk factors for mortality in adults over 60 years of age with cancer of the Centro Médico Naval (CEMENA) in Callao, Peru during 2012–2015. Methods We performed a secondary analysis of data from a prospective cohort carried out from September 2012 to February 2013 in the Geriatrics Department of CEMENA. The outcome variable was mortality at two years of follow-up, while the exposure variable was the risk of sarcopenia assessed using the SARC-F and SARC-CalF scales. We carried out Cox proportional-hazards models to assess the role of SARC-F and SARC-CalF scores as risk factors for mortality. We estimated crude (cHR) and adjusted (aHR) hazard ratios (HR) with their respective 95% confidence intervals (95%CI). Likewise, we calculated the area under the curve (AUC) of both exposure variables in relation to mortality. Results We analyzed data from 922 elderly men with cancer; 43.1% (n=397) were between 60 and 70 years old. 21.5% (n=198) and 45.7% (n=421) were at risk of sarcopenia according to SARC-F and SARC-CalF, respectively, while the incidence of mortality was 22.9% (n=211). In the adjusted Cox regression model, we found that the risk of sarcopenia measured by SARC-F (aHR=2.51; 95%CI: 1.40–2.77) and SARC-CalF (aHR=2.04; 95%CI: 1.55–4.02) was associated with a higher risk of death in older men with cancer. In the diagnostic performance analysis, we found that the AUC for mortality prediction was 0.71 (95%CI: 0.68–0.75) for SARC-F and 0.80 (95%CI: 0.78–0.82) for SARC-CalF. Conclusions The risk of sarcopenia evaluated by SARC-F and SARC-CalF scores was associated with an increased risk of mortality in older men with cancer. Both scales proved to be useful and accessible instruments for the identification of groups at risk of mortality. Electronic Supplementary Material Supplementary material is available in the online version of this article at 10.1007/s12603-022-1844-2.

show abstract

“…Frailty is defined as a decrease in the reserve capacity of the body’s multiple systems that increases the risk of adverse health outcomes because the body’s adaptability and resilience cannot respond when stressful events occur [ 13 – 18 ]. Frailty can be used to predict chemotherapy-related adverse outcomes such as mortality [ 19 , 20 ], chemotherapy drug tolerance [ 16 , 21 ], severe toxicity [ 20 , 22 ], treatment interruption, and hospitalization [ 23 ] in geriatric patients with cancer undergoing chemotherapy. Therefore, the American Society of Clinical Oncology [ 24 ], National Comprehensive Cancer Network [ 25 ], and International Society of Geriatric Oncology [ 26 ] state that the Comprehensive Geriatric Assessment (CGA) should be used to assess the frailty of geriatric patients before they receive cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Association of frailty and chemotherapy-related adverse outcomes in geriatric patients with cancer: a pilot observational study in Taiwan

Tang

Chen

et al. 2021

Aging

View full text Add to dashboard Cite

Frailty and Vulnerability as Predictors of Chemotherapy Toxicity in Older Adults: A Longitudinal Study in Peru

Cited by 12 publications

References 35 publications

The Association Between Cardiometabolic Risk Factors and Frailty in Older Adults: A Systematic Review

The Association Between Cardiometabolic Risk Factors and Frailty in Older Adults: A Systematic Review

SARC-F and SARC-CalF Scores as Mortality Risk Factors in Older Men with Cancer: A Longitudinal Study from Peru

Association of frailty and chemotherapy-related adverse outcomes in geriatric patients with cancer: a pilot observational study in Taiwan

Contact Info

Product

Resources

About